AR042806A1 - Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo - Google Patents
Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animoInfo
- Publication number
- AR042806A1 AR042806A1 ARP030104816A ARP030104816A AR042806A1 AR 042806 A1 AR042806 A1 AR 042806A1 AR P030104816 A ARP030104816 A AR P030104816A AR P030104816 A ARP030104816 A AR P030104816A AR 042806 A1 AR042806 A1 AR 042806A1
- Authority
- AR
- Argentina
- Prior art keywords
- treatment
- disorders
- reabsortion
- carbostirile
- animo
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical class C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 abstract 2
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 abstract 2
- 239000003772 serotonin uptake inhibitor Substances 0.000 abstract 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 abstract 1
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 abstract 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 abstract 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 abstract 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 abstract 1
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 abstract 1
- 229960004372 aripiprazole Drugs 0.000 abstract 1
- 229960001653 citalopram Drugs 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 229960002866 duloxetine Drugs 0.000 abstract 1
- 229960002464 fluoxetine Drugs 0.000 abstract 1
- 229960004038 fluvoxamine Drugs 0.000 abstract 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 229960000600 milnacipran Drugs 0.000 abstract 1
- 229960002296 paroxetine Drugs 0.000 abstract 1
- 229940076279 serotonin Drugs 0.000 abstract 1
- 229960002073 sertraline Drugs 0.000 abstract 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 229960004688 venlafaxine Drugs 0.000 abstract 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Composición farmacéutica que comprende (1) un derivado de carboestirilo y (2) un inhibidor de la reabsorción de serotonina en un portador farmacéuticamente aceptable. El derivado de carboestirilo puede ser aripiprazol o un metabolito del mismo, el cual es un estabilizador del sistema de dopamina-serotonina. El inhibidor de la reabsorción de serotonina puede ser fluoxetina, duloxetina, venlafaxina, milnacipran, citalopram, fluvoxamina, paroxetina o sertralina. La composición farmacéutica de la presente invención resulta de utilidad para el tratamiento de pacientes con trastornos del ánimo, particularmente depresión o un trastorno depresivo profundo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002379003 | 2002-12-27 | ||
US47048103P | 2003-05-14 | 2003-05-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR042806A1 true AR042806A1 (es) | 2005-07-06 |
Family
ID=41212155
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP030104816A AR042806A1 (es) | 2002-12-27 | 2003-12-23 | Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo |
ARP140104496A AR098599A2 (es) | 2002-12-27 | 2014-12-03 | Procedimiento de utilización de una composición farmacéutica que comprende derivados de carboestirilo e inhibidores de la reabsorción de serotonina para preparar un medicamento para el tratamiento de trastornos del animo |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140104496A AR098599A2 (es) | 2002-12-27 | 2014-12-03 | Procedimiento de utilización de una composición farmacéutica que comprende derivados de carboestirilo e inhibidores de la reabsorción de serotonina para preparar un medicamento para el tratamiento de trastornos del animo |
Country Status (9)
Country | Link |
---|---|
US (1) | US8759350B2 (es) |
CN (1) | CN101879166B (es) |
AR (2) | AR042806A1 (es) |
CA (1) | CA2716966C (es) |
GE (2) | GEP20104888B (es) |
MY (1) | MY139551A (es) |
SG (1) | SG154337A1 (es) |
TW (2) | TWI359661B (es) |
UA (1) | UA84692C2 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7053092B2 (en) | 2001-01-29 | 2006-05-30 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1a receptor subtype agonist |
AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
EP1819328A1 (en) * | 2004-10-28 | 2007-08-22 | SK Corporation | Adjunctive therapy for depression |
WO2011057176A1 (en) * | 2009-11-06 | 2011-05-12 | Forest Laboratories Holding Limited | Novel crystalline forms of (1s,2r)-2-(amino methyl)-n,n-diethyl-1-phenyl cyclopropane carboxamide |
JP2013517290A (ja) * | 2010-01-14 | 2013-05-16 | ピエール ファーブル メディカモン | レボミルナシプランの安定した剤形 |
CN108272782B (zh) * | 2011-09-06 | 2021-04-23 | 库尔纳公司 | 小分子在制备治疗Dravet综合征或全面性癫痫伴热性惊厥附加症的药物中的用途 |
WO2014209991A1 (en) * | 2013-06-24 | 2014-12-31 | The Johns Hopkins University | Methods for reducing anxiety and impulsivity in subjects initiating treatment with serotonin reuptake inhibitors |
CA2982898C (en) * | 2015-05-13 | 2023-08-29 | A. Carlsson Research Ab | Combination of dopamine stabilizing agent and an anti-depressive agent to treat a disorder characterized by debilitating fatigue |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4310524A (en) * | 1980-04-11 | 1982-01-12 | Richardson-Merrell, Inc. | TCA Composition and method for rapid onset antidepressant therapy |
US5006528A (en) * | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
US5114976A (en) * | 1989-01-06 | 1992-05-19 | Norden Michael J | Method for treating certain psychiatric disorders and certain psychiatric symptoms |
US5591884A (en) * | 1989-05-31 | 1997-01-07 | Abbott Laboratories | Dopamine agonists |
US5500343A (en) * | 1990-02-07 | 1996-03-19 | Board Of Regents, The University Of Texas System | Allelic association of the human dopamine(D2) receptor gene in compulsive disorders |
US5780051A (en) * | 1992-04-02 | 1998-07-14 | Dynagen, Inc. | Methods and articles of manufacture for nicotine cessation and monitoring nicotine use |
US5663167A (en) | 1992-12-09 | 1997-09-02 | The United States Of America As Represented By The Department Of Health And Human Services | Antipsychotic composition and method of treatment |
IE930485A1 (en) | 1993-06-28 | 1994-12-28 | Hemisphere Ltd | Antidepressant agents with a rapid onset of action |
ZA948357B (en) | 1994-06-16 | 1996-04-24 | Lilly Co Eli | Potentiation of drug response |
EA000745B1 (ru) * | 1995-12-22 | 2000-02-28 | Эли Лилли Энд Компани | Способ лечения депрессии |
EA000976B1 (ru) * | 1996-03-25 | 2000-08-28 | Эли Лилли Энд Компани | Композиция для снятия боли и способ снятия боли |
JP2000507544A (ja) | 1996-03-25 | 2000-06-20 | イーライ・リリー・アンド・カンパニー | 痛みの治療方法 |
US6159963A (en) * | 1996-03-29 | 2000-12-12 | Eli Lilly And Company | Method for treating substance abuse |
IL121076A (en) * | 1996-06-19 | 2000-10-31 | Akzo Nobel Nv | Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors |
ZA977967B (en) | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
ZA982368B (en) | 1997-03-27 | 1998-09-23 | Akzo Nobel Nv | New therapeutic combinations |
JP2001520195A (ja) * | 1997-10-17 | 2001-10-30 | イーライ・リリー・アンド・カンパニー | 医薬の増強 |
GB9801538D0 (en) * | 1998-01-23 | 1998-03-25 | Merck Sharp & Dohme | Pharmaceutical product |
EP1844769A3 (en) * | 1998-04-14 | 2010-02-10 | The General Hospital Corporation | Methods for treating neuropsychiatric disorders |
GB2336534A (en) * | 1998-04-24 | 1999-10-27 | Alec James Coppen | Anti-depressant - Folic Acid Combination |
NZ508035A (en) | 1998-05-08 | 2004-02-27 | Upjohn Co | New drug combinations of A N.A.R.I., namely reboxetine and pindolol |
US6500827B2 (en) * | 1998-05-08 | 2002-12-31 | Pharmacia & Upjohn Company | Drug combinations |
EP1077704A4 (en) | 1998-05-21 | 2002-01-30 | Lilly Co Eli | COMBINATION THERAPY FOR TREATING DEPRESSION |
SK17512000A3 (sk) | 1998-05-22 | 2002-02-05 | Eli Lilly And Company | Liek na liečenie nepoddajnej depresie a farmaceutická kompozícia |
US6960577B2 (en) * | 1998-05-22 | 2005-11-01 | Eli Lilly And Company | Combination therapy for treatment of refractory depression |
US20030027817A1 (en) * | 1998-05-29 | 2003-02-06 | Tollefson Gary Dennis | Combination therapy for treatment of bipolar disorders |
KR20010043731A (ko) | 1998-05-29 | 2001-05-25 | 피터 지. 스트링거 | 양극성 장애의 치료를 위한 조합 치료법 |
JP2002530339A (ja) * | 1998-11-23 | 2002-09-17 | セプラコール, インク. | 2−ヒドロキシメチルオランザピン組成物及び方法 |
US6121259A (en) * | 1998-11-23 | 2000-09-19 | Sepracor Inc. | Olanzapine-N-oxide compositions and methods |
ATE286398T1 (de) * | 1998-11-23 | 2005-01-15 | Sepracor Inc | Desmethylolanzapine enthaltende zusammensetzungen und verfahren |
AU3757500A (en) * | 1999-03-18 | 2000-10-04 | Childrens Hospital Research Foundation | A method of treating bulimia nervosa and related eating disorders by administration of atypical antipsychotic medications |
JP2002541098A (ja) | 1999-04-06 | 2002-12-03 | セプラコア インコーポレーテッド | ジプラシドン代謝産物を用いる神経弛緩薬性障害および関連障害を治療するための方法および組成物 |
US6281207B1 (en) | 1999-09-15 | 2001-08-28 | Reed Richter | Treatment of movement disorders by administration of mirtazapine |
US6572890B2 (en) | 2000-01-13 | 2003-06-03 | Osmotica Corp. | Osmotic device containing venlafaxine and an anti-psychotic agent |
US6599532B2 (en) * | 2000-01-13 | 2003-07-29 | Osmotica Corp. | Osmotic device containing alprazolam and an antipsychotic agent |
US6322503B1 (en) * | 2000-02-17 | 2001-11-27 | G. Roger Sparhawk, Jr. | Method of diagnosing, tracking, and treating depression |
DE10018834A1 (de) * | 2000-04-15 | 2001-10-25 | Lohmann Therapie Syst Lts | Transdermale oder transmucosale Darreichungsformen mit einer nicotinhaltigen Wirkstoffkombination zur Raucherentwöhnung |
CA2364211A1 (en) | 2000-12-05 | 2002-06-05 | Phillip Branch Chappell | Combination treatment for depression, anxiety and psychosis |
AU2002232470B2 (en) * | 2001-01-02 | 2005-11-03 | Pharmacia & Upjohn Company Llc | New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents |
AR032641A1 (es) * | 2001-01-29 | 2003-11-19 | Otsuka Pharma Co Ltd | Agonista de subtipo de receptor 5-ht 1a. |
US7053092B2 (en) * | 2001-01-29 | 2006-05-30 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1a receptor subtype agonist |
US20020123490A1 (en) | 2001-03-01 | 2002-09-05 | Pfizer Inc. | Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis |
CA2440374A1 (en) | 2001-03-14 | 2002-09-19 | Takayuki Maruyama | A pharmaceutical composition for the treatment of depression comprising the ep1 antagonist as active ingredient |
MXPA03009532A (es) | 2001-04-19 | 2004-02-12 | Warner Lambert Co | Aminoacidos biciclicos o triciclicos condensados. |
CA2445528A1 (en) * | 2001-04-26 | 2002-11-07 | Ortho-Mcneil Pharmaceutical, Inc. | Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics |
DE10129320A1 (de) * | 2001-06-19 | 2003-04-10 | Norbert Mueller | Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen |
AR033485A1 (es) * | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
US6582737B2 (en) * | 2001-09-25 | 2003-06-24 | Peirce Management, Llc | Pharmaceutical composition containing two active ingredients for smoking cessation |
WO2003066039A1 (en) | 2002-02-08 | 2003-08-14 | Abbott Laboratories | Combination therapy for treatment of schizophrenia |
EP1336406A1 (en) * | 2002-02-14 | 2003-08-20 | Solvay Pharmaceuticals B.V. | Partial dopamine-D2 receptor agonist plus serotonin and/or noradrenaline inhibitory activity |
WO2003101492A2 (en) | 2002-05-30 | 2003-12-11 | Neurosearch A/S | Combination of atypical antipsychotic and serotonin reuptake inhibitor for the treatment of chronic pain |
WO2004011031A1 (en) | 2002-07-29 | 2004-02-05 | Potomac, Pharma, Llc. | Antipsychotic combination therapies and compositions of an alpha-2 adrenergic receptor antagonist and an atypical antipsychotic neuroleptic |
WO2004010932A2 (en) | 2002-07-30 | 2004-02-05 | Peter Migaly | Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions |
CA2503121A1 (en) | 2002-10-25 | 2004-05-13 | Collegium Pharmaceutical, Inc. | Pulsatile release compositions of milnacipran |
US20040132826A1 (en) | 2002-10-25 | 2004-07-08 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
BRPI0413726A (pt) | 2003-09-09 | 2006-11-07 | Pfizer Prod Inc | combinação de inibidores da recaptação de serotonina e inibidores da recaptação de norepinefrina |
WO2005051488A1 (en) | 2003-11-26 | 2005-06-09 | Pfizer Products Inc. | Combination of dopamine agonists and monoamine reuptake inhibitors |
EP1713486A4 (en) * | 2003-12-02 | 2009-04-29 | Sheldon Leslie James | COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY |
-
2003
- 2003-12-23 AR ARP030104816A patent/AR042806A1/es not_active Application Discontinuation
- 2003-12-24 TW TW098120639A patent/TWI359661B/zh not_active IP Right Cessation
- 2003-12-24 MY MYPI20034985A patent/MY139551A/en unknown
- 2003-12-24 TW TW092136756A patent/TWI315669B/zh not_active IP Right Cessation
- 2003-12-25 UA UAA200506361A patent/UA84692C2/ru unknown
- 2003-12-25 GE GEAP20039656A patent/GEP20104888B/en unknown
- 2003-12-25 CN CN200910209720.8A patent/CN101879166B/zh not_active Expired - Lifetime
- 2003-12-25 GE GEAP20038869A patent/GEP20074225B/en unknown
- 2003-12-25 CA CA2716966A patent/CA2716966C/en not_active Expired - Lifetime
- 2003-12-25 US US10/540,577 patent/US8759350B2/en active Active
- 2003-12-25 SG SG200704097-5A patent/SG154337A1/en unknown
-
2014
- 2014-12-03 AR ARP140104496A patent/AR098599A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN101879166A (zh) | 2010-11-10 |
TW200940058A (en) | 2009-10-01 |
CA2716966A1 (en) | 2004-07-22 |
GEP20074225B (en) | 2007-10-25 |
MY139551A (en) | 2009-10-30 |
TW200507846A (en) | 2005-03-01 |
TWI359661B (en) | 2012-03-11 |
UA84692C2 (ru) | 2008-11-25 |
CN101879166B (zh) | 2014-03-19 |
SG154337A1 (en) | 2009-08-28 |
GEP20104888B (en) | 2010-02-10 |
CA2716966C (en) | 2012-12-18 |
US8759350B2 (en) | 2014-06-24 |
AR098599A2 (es) | 2016-06-01 |
TWI315669B (en) | 2009-10-11 |
US20060154938A1 (en) | 2006-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP055885A (es) | Derivados de carbostirilo e inhibidores de la recaptacion de serotonina que sirven para el tratamiento de desordenes en el humor | |
Hale et al. | Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study | |
Kirino | Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability | |
AR098599A2 (es) | Procedimiento de utilización de una composición farmacéutica que comprende derivados de carboestirilo e inhibidores de la reabsorción de serotonina para preparar un medicamento para el tratamiento de trastornos del animo | |
CO4900058A1 (es) | Terapia de combinacion para el tratamiento de psicosis | |
NZ615591A (en) | Combinations comprising brexpiprazole or a salt thereof and a second drug for use in the treatment of a cns disorder | |
RS20050392A (en) | Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor | |
BRPI0510142A (pt) | compostos, composições e métodos para estabilizar a transtiretina e inibir a duplicação defeituosa da transtiretina | |
TR200401291T4 (tr) | Depresyon, obsesif kompülsif bozukluk ve psikozda kullanılmak üzre bir serotonin reuptake inhibitörü ve bir atipik antipsikotik kombinasyonu | |
BRPI0415769A (pt) | alcanaminas de diidrobenzofuranila e composições farmacêuticas contendo-as | |
BRPI0411665A (pt) | uso de agomelatina ou de um seu sal farmaceuticamente aceitável, composição farmacêutica ou kit, e, métodos para o tratamento de doenças ou distúrbios responsivos a um inibidor da recaptação de serotonina e para aumentar e/ou proporcionar inìcio mais rápido do efeito terapêutico de um inibidor da recaptação de serotonina | |
CO6260011A2 (es) | Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del acido 4-hidroxi-4-metil-piperidin-1- carboxilico para el tratamiento del trastorno por estres postraumatico | |
Shao et al. | Discovery of N-methyl-1-(1-phenylcyclohexyl) ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor | |
BRPI0413750A (pt) | uso de loxapina ou de um seu sal farmaceuticamente aceitável, composição farmacêutica, e, kit | |
RS51669B (en) | NEW DRUG COMBINATIONS AS ANTIDEPRESSIVE | |
AR056056A1 (es) | Asociacion entre la agomelatina y un inhibidor de la recaptacion de la noradrenalina y las composiciones farmaceuticas que las contienen | |
WO2003101492A3 (en) | Combination of atypical antipsychotic and serotonin reuptake inhibitor for the treatment of chronic pain | |
Murdoch et al. | Spotlight on escitalopram in the management of major depressive disorder | |
PE20080431A1 (es) | Composicion farmaceutica que contiene en asociacion saredutant y un inhibidor selectivo de la recaptacion de serotonina o un inhibidor de la recaptacion de serotonina/norepinefrina | |
BRPI0513386A (pt) | inibidores de reabsorção de norepinefrina de quinoxalinona para o tratamento de distúrbios do sistema nervoso central | |
MX2022011479A (es) | Combinacion de antipsicotico atipico e inhibidor de la recaptacion de serotonina. | |
Kirino | Antidepressant efficacy of escitalopram in major depressive disorder | |
AR039117A1 (es) | El uso de 3-(1-(2-(1-acetil-2,3-dihidro-1h-indol-3-il) etil) -3,6-dihidro-2h-piridin-4-il)-6-cloro-1h-indol o sus enantiomeros para el tratamiento de enfermedades y trastornos que responden a la inhibicion de la recaptacion de 5-ht (serotonina) | |
BRPI0413749A (pt) | uso de amoxapina ou de um sal farmaceuticamente aceitável, composição farmacêutica, e, kit | |
NO20081723L (no) | Assosiasjon av beta 3 reseotoragonist og monoamin gjenopptaksinhibator, farmasoytisk sammensetting inneholdende samme og terapeutisk anvendelse derav |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |